A systematic review of immune checkpoint inhibitors in endometrial cancer

1

Endometrial cancer is a prevalent gynecological malignancy with increasing incidence, necessitating advanced treatment strategies.
2

The study analyzed 829 publications from the WoSCC and 279 from PubMed, highlighting significant international collaboration.
3

Key research hotspots include microsatellite instability, PD-1, PD-L1, and various immune checkpoint inhibitors like pembrolizumab.
4

The TCGA molecular typing system is transforming endometrial cancer treatment from traditional methods to precision immunotherapy.
5

Makker Vicky and Memorial Sloan Kettering Cancer Center are identified as leading contributors in the field of immune checkpoint inhibitors.